{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:31:24Z","timestamp":1771363884835,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T00:00:00Z","timestamp":1536796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T00:00:00Z","timestamp":1536796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Calprotectin (CPT) is released during inflammation, also in the context of atherosclerosis. The link between CPT and the atherosclerotic process was evaluated in several diseases. However, studies in axial spondyloarthritis (axSpA), associated with a high incidence of subclinical atherosclerosis, are scarce. Therefore, we assessed the association of CPT with subclinical atherosclerosis and metabolic risk factors in axSpA. CPT serum levels were measured by enzyme-linked immunosorbent assay in 163 axSpA patients and 63 controls. Subclinical atherosclerosis was determined in patients by carotid ultrasonography (assessing the presence\/absence of carotid plaques and carotid intima-media thickness [cIMT]). Data on inflammation, disease activity, lipid profile and treatment were collected to evaluate its relationship with CPT. axSpA patients evidenced lower CPT levels than controls. CPT showed no association with plaques or cIMT in axSpA. CPT and HDL-cholesterol negatively correlated, while a positive association of CPT with the atherogenic index was disclosed. Additionally, axSpA patients with C-reactive protein values at diagnosis higher than 3\u2009mg\/L displayed higher CPT levels. Our study shows no relationship between CPT and markers of subclinical atherosclerosis in axSpA. Nevertheless, it demonstrates an association of CPT with adverse lipid profiles and inflammatory biomarkers, which could further influence on the development of atherosclerosis.<\/jats:p>","DOI":"10.1038\/s41598-018-32199-3","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T09:13:29Z","timestamp":1536311609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of circulating calprotectin with lipid profile in axial spondyloarthritis"],"prefix":"10.1038","volume":"8","author":[{"given":"Fernanda","family":"Genre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Rueda-Gotor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Remuzgo-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Corrales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Mijares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Exp\u00f3sito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Portilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-1328","authenticated-orcid":false,"given":"Oreste","family":"Gualillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-2689","authenticated-orcid":false,"given":"Raquel","family":"L\u00f3pez-Mej\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,13]]},"reference":[{"key":"32199_CR1","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1161\/CIRCRESAHA.117.309419","volume":"120","author":"MC Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez, M. C. & Andriantsitohaina, R. Extracellular Vesicles in Metabolic Syndrome. Circ Res. 120, 1674\u20131686 (2017).","journal-title":"Circ Res."},{"key":"32199_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2017.03.008","volume":"120","author":"G Pucci","year":"2017","unstructured":"Pucci, G. et al. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res. 120, 34\u201342 (2017).","journal-title":"Pharmacol Res."},{"key":"32199_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.trsl.2017.01.001","volume":"183","author":"JD Tune","year":"2017","unstructured":"Tune, J. D., Goodwill, A. G., Sassoon, D. J. & Mather, K. J. Cardiovascular consequences of metabolic syndrome. Transl Res. 183, 57\u201370 (2017).","journal-title":"Transl Res."},{"key":"32199_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000449028","volume":"32","author":"S Brede","year":"2016","unstructured":"Brede, S., Serfling, G., Klement, J., Schmid, S. M. & Lehnert, H. Clinical Scenario of the Metabolic Syndrome. Visc Med. 32, 336\u2013341 (2016).","journal-title":"Visc Med."},{"key":"32199_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrrheum.2014.121","volume":"10","author":"G Kerekes","year":"2014","unstructured":"Kerekes, G. et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 10, 691\u2013696 (2014).","journal-title":"Nat Rev Rheumatol."},{"key":"32199_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/MD.0b013e3181c10773","volume":"88","author":"C Gonzalez-Juanatey","year":"2009","unstructured":"Gonzalez-Juanatey, C. et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore). 88, 358\u2013365 (2009).","journal-title":"Medicine (Baltimore)."},{"key":"32199_CR7","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.jacc.2009.11.075","volume":"55","author":"V Nambi","year":"2010","unstructured":"Nambi, V. et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 55, 1600\u20131607 (2010).","journal-title":"J Am Coll Cardiol."},{"key":"32199_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.semarthrit.2008.01.012","volume":"38","author":"C Gonzalez-Juanatey","year":"2009","unstructured":"Gonzalez-Juanatey, C., Llorca, J., Martin, J. & Gonzalez-Gay, M. A. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum. 38, 366\u2013371 (2009).","journal-title":"Semin Arthritis Rheum."},{"key":"32199_CR9","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/art.30265","volume":"63","author":"MR Evans","year":"2011","unstructured":"Evans, M. R. et al. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum. 63, 1211\u20131220 (2011).","journal-title":"Arthritis Rheum."},{"key":"32199_CR10","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1136\/annrheumdis-2013-203688","volume":"72","author":"A Corrales","year":"2013","unstructured":"Corrales, A. et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 72, 1764\u20131770 (2013).","journal-title":"Ann Rheum Dis."},{"key":"32199_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/annrheumdis-2012-203101","volume":"73","author":"A Corrales","year":"2014","unstructured":"Corrales, A. et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis. 73, 722\u2013727 (2014).","journal-title":"Ann Rheum Dis."},{"key":"32199_CR12","first-page":"885","volume":"34","author":"J Rueda-Gotor","year":"2016","unstructured":"Rueda-Gotor, J. et al. Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. Clin Exp Rheumatol. 34, 885\u2013892 (2016).","journal-title":"Clin Exp Rheumatol."},{"key":"32199_CR13","first-page":"315","volume":"33","author":"J Rueda-Gotor","year":"2015","unstructured":"Rueda-Gotor, J. et al. Atherosclerotic disease in axial spondyloarthritis: increased frequency of carotid plaques. Clin Exp Rheumatol. 33, 315\u2013320 (2015).","journal-title":"Clin Exp Rheumatol."},{"key":"32199_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jbspin.2013.03.019","volume":"81","author":"C Papagoras","year":"2014","unstructured":"Papagoras, C. et al. Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine. 81, 57\u201363 (2014).","journal-title":"Joint Bone Spine."},{"key":"32199_CR15","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han, C. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 33, 2167\u20132172 (2006).","journal-title":"J Rheumatol."},{"key":"32199_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/acr.20364","volume":"63","author":"S Mathieu","year":"2011","unstructured":"Mathieu, S., Gossec, L., Dougados, M. & Soubrier, M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 63, 557\u2013563 (2011).","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"32199_CR17","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1002\/art.30581","volume":"63","author":"SM Szabo","year":"2011","unstructured":"Szabo, S. M. et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 63, 3294\u20133304 (2011).","journal-title":"Arthritis Rheum."},{"key":"32199_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/acr.20408","volume":"63","author":"A Bremander","year":"2011","unstructured":"Bremander, A., Petersson, I. F., Bergman, S. & Englund, M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken). 63, 550\u2013556 (2011).","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"32199_CR19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s10067-006-0380-5","volume":"26","author":"D Malesci","year":"2007","unstructured":"Malesci, D. et al. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol. 26, 710\u2013714 (2007).","journal-title":"Clin Rheumatol."},{"key":"32199_CR20","first-page":"292","volume":"27","author":"JA Papadakis","year":"2009","unstructured":"Papadakis, J. A. et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol. 27, 292\u2013298 (2009).","journal-title":"Clin Exp Rheumatol."},{"key":"32199_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.berh.2016.10.006","volume":"30","author":"S Casta\u00f1eda","year":"2016","unstructured":"Casta\u00f1eda, S., Nurmohamed, M. T. & Gonz\u00e1lez-Gay, M. A. Cardiovascular disease in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 30, 851\u2013869 (2016).","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"32199_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.trsl.2015.05.006","volume":"167","author":"J Shen","year":"2016","unstructured":"Shen, J., Shang, Q. & Tam, L. S. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Transl Res. 167, 138\u2013151 (2016).","journal-title":"Transl Res."},{"key":"32199_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arcmed.2013.11.007","volume":"45","author":"L Ch\u00e1vez-S\u00e1nchez","year":"2014","unstructured":"Ch\u00e1vez-S\u00e1nchez, L. et al. Innate immune system cells in atherosclerosis. Arch Med Res. 45, 1\u201314 (2014).","journal-title":"Arch Med Res."},{"key":"32199_CR24","first-page":"71","volume":"16","author":"A Duran","year":"2016","unstructured":"Duran, A. et al. Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Bosn J Basic Med Sci. 16, 71\u201374 (2016).","journal-title":"Bosn J Basic Med Sci."},{"key":"32199_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X","volume":"43","author":"M Frosch","year":"2000","unstructured":"Frosch, M. et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 43, 628\u2013637 (2000).","journal-title":"Arthritis Rheum."},{"key":"32199_CR26","first-page":"43","volume":"24","author":"PT Larsson","year":"2005","unstructured":"Larsson, P. T., Hallerstam, S., Rosfors, S. & Wall\u00e9n, N. H. Circulating markers of inflammation are related to carotid artery atherosclerosis. Int Angiol. 24, 43\u201351 (2005).","journal-title":"Int Angiol."},{"key":"32199_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/1471-2261-14-196","volume":"14","author":"L Pedersen","year":"2014","unstructured":"Pedersen, L. et al. Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients. BMC Cardiovasc Disord. 14, 196 (2014).","journal-title":"BMC Cardiovasc Disord."},{"key":"32199_CR28","first-page":"1006","volume":"34","author":"GM Balarini","year":"2016","unstructured":"Balarini, G. M. et al. Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol. 34, 1006\u20131012 (2016).","journal-title":"Clin Exp Rheumatol."},{"key":"32199_CR29","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1172\/JCI86924","volume":"127","author":"SR Langley","year":"2017","unstructured":"Langley, S. R. et al. Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques. J Clin Invest. 127, 1546\u20131560 (2017).","journal-title":"J Clin Invest."},{"key":"32199_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/ajh.2012.12","volume":"25","author":"K Angel","year":"2012","unstructured":"Angel, K. et al. Effect of 1-year anti-TNF-\u03b1 therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens. 25, 644\u2013650 (2012).","journal-title":"Am J Hypertens."},{"key":"32199_CR31","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1177\/1535370216681551","volume":"242","author":"F Ometto","year":"2017","unstructured":"Ometto, F. et al. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood). 242, 859\u2013873 (2017).","journal-title":"Exp Biol Med (Maywood)."},{"key":"32199_CR32","doi-asserted-by":"publisher","first-page":"828354","DOI":"10.1155\/2013\/828354","volume":"2013","author":"A Schiopu","year":"2013","unstructured":"Schiopu, A. & Cotoi, O. S. S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediators Inflamm. 2013, 828354 (2013).","journal-title":"Mediators Inflamm."},{"key":"32199_CR33","doi-asserted-by":"publisher","first-page":"c3369","DOI":"10.1136\/bmj.c3369","volume":"341","author":"PF van Rheenen","year":"2010","unstructured":"van Rheenen, P. F., Van de Vijver, E. & Fidler, V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 341, c3369 (2010).","journal-title":"BMJ."},{"key":"32199_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/path.1758","volume":"206","author":"L De Rycke","year":"2005","unstructured":"De Rycke, L. et al. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol. 206, 17\u201327 (2005).","journal-title":"J Pathol."},{"key":"32199_CR35","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/art.21914","volume":"54","author":"E Kruithof","year":"2006","unstructured":"Kruithof, E. et al. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum. 54, 1795\u20131804 (2006).","journal-title":"Arthritis Rheum."},{"key":"32199_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3109\/00365521.2011.648953","volume":"47","author":"E Klingberg","year":"2012","unstructured":"Klingberg, E., Carlsten, H., Hilme, E., Hedberg, M. & Forsblad-d\u2019Elia, H. Calprotectin in ankylosing spondylitis\u2013frequently elevated in feces, but normal in serum. Scand J Gastroenterol. 47, 435\u2013444 (2012).","journal-title":"Scand J Gastroenterol."},{"key":"32199_CR37","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1136\/annrheumdis-2014-205506","volume":"73","author":"MC Turina","year":"2014","unstructured":"Turina, M. C. et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis. 73, 1746\u20131748 (2014).","journal-title":"Ann Rheum Dis."},{"key":"32199_CR38","first-page":"4057","volume":"68","author":"Z Stavre","year":"2016","unstructured":"Stavre, Z., Maeda, Y. & Gravallese, E. M. Calprotectin Is Highly Upregulated in Inflamed Axial Entheses in SKG Mice [abstract]. Arthritis Rheumatol. 68, 4057\u20134058 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"32199_CR39","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jbspin.2011.02.012","volume":"78","author":"C Prati","year":"2011","unstructured":"Prati, C., Claudepierre, P., Pham, T. & Wendling, D. Mortality in spondylarthritis. Joint Bone Spine. 78, 466\u2013470 (2011).","journal-title":"Joint Bone Spine."},{"key":"32199_CR40","first-page":"860651","volume":"2014","author":"F Genre","year":"2014","unstructured":"Genre, F. et al. Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis. Biomed Res Int. 2014, 860651 (2014).","journal-title":"Biomed Res Int."},{"key":"32199_CR41","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/annrheumdis-2015-208025","volume":"75","author":"H Cypers","year":"2016","unstructured":"Cypers, H. et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 75, 1357\u20131362 (2016).","journal-title":"Ann Rheum Dis."},{"key":"32199_CR42","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/JIM.0000000000000095","volume":"62","author":"P Oktayoglu","year":"2014","unstructured":"Oktayoglu, P. et al. Elevated serum levels of calprotectin (myeloid-related protein 8\/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 62, 880\u2013884 (2014).","journal-title":"J Investig Med."},{"key":"32199_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s13075-014-0413-4","volume":"16","author":"MC Turina","year":"2014","unstructured":"Turina, M. C., Yeremenko, N., Paramarta, J. E., De Rycke, L. & Baeten, D. Calprotectin (S100A8\/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 16, 413 (2014).","journal-title":"Arthritis Res Ther."},{"key":"32199_CR44","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1007\/s10067-016-3448-x","volume":"35","author":"L Gupta","year":"2016","unstructured":"Gupta, L., Bhattacharya, S., Agarwal, V. & Aggarwal, A. Elevated levels of serum MRP8\/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease. Clin Rheumatol. 35, 3075\u20133079 (2016).","journal-title":"Clin Rheumatol."},{"key":"32199_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13075-016-1180-1","volume":"18","author":"A Levitova","year":"2016","unstructured":"Levitova, A. et al. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Res Ther. 18, 275 (2016).","journal-title":"Arthritis Res Ther."},{"key":"32199_CR46","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde, D. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 76, 978\u2013991 (2017).","journal-title":"Ann Rheum Dis."},{"key":"32199_CR47","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5114\/reum.2016.64907","volume":"54","author":"M Kope\u0107-M\u0119drek","year":"2016","unstructured":"Kope\u0107-M\u0119drek, M., Widuchowska, M. & Kucharz, E. J. Calprotectin in rheumatic diseases: a review. Reumatologia. 54, 306\u2013309 (2016).","journal-title":"Reumatologia."},{"key":"32199_CR48","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/art.10988","volume":"48","author":"D Kane","year":"2003","unstructured":"Kane, D. et al. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum. 48, 1676\u20131685 (2003).","journal-title":"Arthritis Rheum."},{"key":"32199_CR49","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3899\/jrheum.140628","volume":"42","author":"M Abildtrup","year":"2015","unstructured":"Abildtrup, M., Kingsley, G. H. & Scott, D. L. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 42, 760\u2013770 (2015).","journal-title":"J Rheumatol."},{"key":"32199_CR50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1161\/ATVBAHA.113.302432","volume":"34","author":"OS Cotoi","year":"2014","unstructured":"Cotoi, O. S. et al. Plasma S100A8\/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arterioscler Thromb Vasc Biol. 34, 202\u2013210 (2014).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"32199_CR51","doi-asserted-by":"publisher","first-page":"e7419","DOI":"10.1371\/journal.pone.0007419","volume":"4","author":"OH Mortensen","year":"2009","unstructured":"Mortensen, O. H. et al. Calprotectin\u2013a novel marker of obesity. PLoS One. 4, e7419 (2009).","journal-title":"PLoS One."},{"key":"32199_CR52","doi-asserted-by":"publisher","first-page":"S462","DOI":"10.1086\/315611","volume":"181","author":"W Khovidhunkit","year":"2000","unstructured":"Khovidhunkit, W. et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis. 181, S462\u2013S472 (2000).","journal-title":"J Infect Dis."},{"key":"32199_CR53","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/01.CIR.0000125690.80303.A8","volume":"109","author":"PM Ridker","year":"2004","unstructured":"Ridker, P. M. & Cook, N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 109, 1955\u20131959 (2004).","journal-title":"Circulation."},{"key":"32199_CR54","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 68, 777\u2013783 (2009).","journal-title":"Ann Rheum Dis."},{"key":"32199_CR55","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden, S., Valkenburg, H. A. & Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27, 361\u2013368 (1984).","journal-title":"Arthritis Rheum."},{"key":"32199_CR56","first-page":"302","volume":"36","author":"F Genre","year":"2018","unstructured":"Genre, F. et al. Implication of osteoprotegerin and sclerostin in axial spondyloarthritis cardiovascular disease: study of 163 Spanish patients. Clin Exp Rheumatol. 36, 302\u2013309 (2018).","journal-title":"Clin Exp Rheumatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32199-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:42:50Z","timestamp":1671615770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32199-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["32199"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-32199-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,13]]},"assertion":[{"value":"19 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13728"}}